spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Gram-positive bacteria 

 HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA
 HSMN NewsFeed - 1 Feb 2021
Galderma Receives FDA Approval for Restylane(R) Defyne for Chin Augmentation
Devices Dermatology FDA
 HSMN NewsFeed - 5 May 2020
Galderma Receives FDA Approval For Restylane(R) Kysse, A New Hyaluronic Acid (HA) Filler Specifically Designed And Indicated To Add Fullness To The Lips And Help Smooth The Wrinkles Above The Mouth
Devices Dermatology FDA
 HSMN NewsFeed - 3 Sep 2019
Allergan Receives FDA Approval of Juvéderm VOLUMA(R) XC For Mid-Face Injection Via Cannula
Biopharmaceuticals Devices Dermatology FDA
 HSMN NewsFeed - 6 Nov 2018
Cumberland Pharmaceuticals To Acquire VIBATIV(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Nov 2018
Galderma Announces FDA Approval of Restylane(R) Lyft For Midface Injection via Cannula
Devices Dermatology FDA
 HSMN NewsFeed - 21 May 2018
Nestlé Skin Health Announces the FDA Approval of Restylane(R) Lyft for Hands, the First and Only Hyaluronic Acid (HA) Dermal Filler for Use in the Back of Hands
Devices Dermatology FDA
 HSMN NewsFeed - 23 Apr 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at 2018 ECCMID(TM) Conference
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing
 HSMN NewsFeed - 22 May 2017
Spero Therapeutics Appoints Joel Sendek as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2017
JUVÉDERM VOLLURE(TM) XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21
Devices Dermatology FDA
 HSMN NewsFeed - 8 Mar 2017
Spero Therapeutics Secures $51.7 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 12 Dec 2016
Galderma Announces FDA Approval of Restylane(R) Refyne and Restylane(R) Defyne Dermal Fillers for Treatment of "Laugh Lines"
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch
 HSMN NewsFeed - 26 Sep 2016
MicuRx Closes $55 Million Series C Financing to Support Development of Next-Generation Antibiotic MRX-I
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 15 Sep 2016
Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 10 Jun 2016
Galderma Celebrates 20th Global Anniversary of Restylane(R)
Biopharmaceuticals Devices Dermatology
 HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Feb 2016
Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Oct 2015
U.S. FDA Approves JUVEDERM(R) ULTRA XC for Use in Lips
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 2 Jul 2015
Galderma Receives FDA Approval to Market Restylane(R) Lyft with Lidocaine to Correct Age Related Volume Loss in the Cheek Area
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 30 Mar 2015
The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(R) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jan 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Dec 2014
Basilea Announces Launch of Antibiotic Zevtera(R) (ceftobiprole medocaril) in Germany
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 17 Nov 2014
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jul 2014
Quidel Receives FDA Clearance for Its Hand-Held Molecular Diagnostic Test for Group A Strep
Diagnostics FDA
 HSMN NewsFeed - 18 Jul 2014
Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 5 Jun 2014
ORBACTIV(TM) (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2013
FDA Approves JUVÉDERM VOLUMA(TM) XC
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 25 Jun 2013
BioFire Receives FDA Clearance for the FilmArray(R) Blood Culture Identification Panel
Diagnostics FDA
 HSMN NewsFeed - 7 Nov 2011
Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Apr 2011
Durata Therapeutics Initiates Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2010
Cubist Pharmaceuticals Receives FDA Approval for 2-Minute IV Injection of CUBICIN
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2010
FDA Advisory Committee Recommends Approval of Forest Laboratories' Ceftaroline Fosamil for the Treatment of Community Acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2010
Advanced Life Sciences Achieves Special Protocol Assessment Agreement With FDA for Restanza in Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Feb 2010
Medicis Receives Approval for RESTYLANE(R) and PERLANE(R) With Lidocaine
Devices Dermatology FDA
 HSMN NewsFeed - 21 Dec 2009
Newly Formed Durata Therapeutics Acquires Pfizer's Vicuron Subsidiary
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 11 Dec 2009
Trial Date Set for CUBICIN(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2009
GSK and Nabi Announce Agreement for NicVAX(R), a Vaccine for Nicotine Addiction
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2009
Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Sep 2009
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2009
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2009
Cempra Pharmaceuticals Closes $46 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Jan 2009
The Medicines Company to Acquire Targanta Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 1 Oct 2008
Advanced Life Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region
Biopharmaceuticals
 HSMN NewsFeed - 1 Oct 2008
Advanced Life Sciences Announces NDA Submission for Cethromycin in Community Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 9 Sep 2008
Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
Biopharmaceuticals Regulatory FDA
 HSMN NewsFeed - 30 Jun 2008
Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2008
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2008
Protez Pharmaceuticals to Be Acquired by Novartis
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Apr 2008
Nabi Biopharmaceuticals Announces Settlement of Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 12 Mar 2008
Immtech Announces Update on Business Operations
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2008
FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jan 2008
Nabi Biopharmaceuticals Names Dr. Raafat E.F. Fahim as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Dec 2007
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2007
Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2007
FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 8 Oct 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 18 Sep 2007
New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
Biopharmaceuticals
 HSMN NewsFeed - 18 Sep 2007
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Biopharmaceuticals
 HSMN NewsFeed - 6 Sep 2007
Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 6 Sep 2007
Cubist Pharmaceuticals' CUBICIN Approved for Additional Indications in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Jul 2007
Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jul 2007
Positive Opinion for Expanded Label of CUBICIN Received from European Regulatory Authority; Decision Expected This September
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jul 2007
Trius Therapeutics Recruits Former J&J Clinician as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2007
Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
Trius Therapeutics Recruits Merck Executive to Lead Drug Development Efforts
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2007
Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 May 2007
Nabi Biopharmaceuticals Announces Positive Results of Phase IIb Trial of NicVAX
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2007
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Apr 2007
Nabi Biopharmaceuticals Announces Agreement to Sell Aloprim(TM)
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Theravance Announces FDA Acceptance of Telavancin NDA
Biopharmaceuticals
 HSMN NewsFeed - 15 Feb 2007
Nabi Biopharmaceuticals Announces Resignation of Thomas McLain as CEO and Appointment of Leslie Hudson as Interim CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2007
Targanta Announces $70 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jan 2007
Nabi Biopharmaceuticals Announces Initiation of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2006
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2006
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
Nabi Biopharmaceuticals Signs Definitive Agreement To Sell PhosLo(R) To Fresenius Medical Care
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Oct 2006
Fresenius Medical Care to Acquire Phosphate Binder Business from Nabi Biopharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Oct 2006
Immtech Pharmaceuticals Announces Antimicrobial Pipeline Progress
Biopharmaceuticals
 HSMN NewsFeed - 10 Oct 2006
Theravance Announces Additional Results From Successful Phase 3 Telavancin Complicated Skin and Skin Structure Program
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2006
Nabi Biopharmaceuticals Board Authorizes Exploration of Strategic Alternatives to Further Enhance Shareholder Value
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2006
Nabi Biopharmaceuticals Releases New Data which Demonstrate Superior Serum Phosphorus Control with PhosLo(R) (calcium acetate) over Sevelamer
Biopharmaceuticals
 HSMN NewsFeed - 13 Jul 2006
Nabi Biopharmaceuticals Receives Positive Opinion from FDA Blood Products Advisory Committee for Nabi-HB(TM) Intravenous
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jun 2006
Nabi Biopharmaceuticals Secures Agreement with Kedrion to Co-Develop and Commercialize Civacir(R) in Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 May 2006
Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program With Investigational Antibiotic, Telavancin
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 67

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 67 additional stories matching:
Gram-positive bacteria
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!